NCT07062354View on ClinicalTrials.gov

Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2029

Conditions

Head &Amp; Neck CancerHead &Amp; Neck Squamous Cell Carcinoma

Interventions

DRUG

Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)

Carboplatin + Paclitaxel + Amivantamab hyaluronidase

Sponsors

Collaborators (1)

Janssen Medical Affairs

All Listed Sponsors

collaborator

Janssen Medical Affairs

INDUSTRY

collaborator

SWOG Clinical Trials Partnerships, LLC

OTHER

lead

SWOG Cancer Research Network

NETWORK